Kickoff meeting for investigator-initiated clinical trial of our 2nd therapeutic candidate for TDP43 protein-opathy was held

Nanjing Medical University Sir Run Run Hospital’s Department of Neurology (http://en.nydsrrsh.com/kszj/kszj.aspx?mtt=1&mt=7) held a kickoff meeting regarding the investigator-initiated clinical trial of a TDP43 aggregation inhibitor in muscle cells discovered by SOCIUM Inc. (https://socium.co.jp/).

The meeting took place on November 28 at Nanjing Medical University Sir Run Run Hospital (http://en.nydsrrsh.com/). Attendees included Professor Jin Qingwen (Principal Investigator, Sir Run Run Hospital), Professor Zhang Renliang (Sir Run Run Hospital), Professor Han Feng (School of Pharmacy), and Professor Chen Dongyin (School of Pharmacy), along with the responsible doctors, responsible nurses, and SOCIUM Inc. CEO Horimoto. During the meeting, the clinical trial protocol booklet was distributed. Following greetings from the four Nanjing Medical University professors and a greeting from Dr. Horimoto, all participants discussed and confirmed the protocol.

Two drugs from our “Umbrella Drug Discovery” (https://socium.co.jp/drug_discovery/) initiative have now entered investigator-initiated clinical trials (Ref: https://socium.co.jp/2025/11/17/2025111701/). Although the target cell types differ—neuronal cells for one and muscle cells for the other—both drugs are therapeutic agents expected to inhibit TDP43 aggregation. They represent candidate treatments for the broad spectrum of TDP43 protein-opathy, a group of rare diseases. Our wish is to deliver drugs as quickly as possible to the many patients suffering from these diseases, for which very few effective treatments exist.